Back to mobile site

Roth Capital Resumes Intec Pharma Ltd. (NTEC) at Buy

October 5, 2018 8:37 AM EDT Send to a Friend
Roth Capital analyst Scott Henry resumes coverage on Intec Pharma Ltd. (NASDAQ: NTEC) with a Buy rating and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login